Trial Profile
Safety and Efficacy of Octreotide LAR Depot in Left Ventricular Assist Device (LVAD) Associate Gastrointestinal (GI)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Gastrointestinal haemorrhage
- Focus Adverse reactions
- 28 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Apr 2015 New trial record